The District Energy-Efficient Retrofitting of Torrelago (Laguna de Duero – Spain)

The urban growth is estimated to reach up the 66 % by 2050 and consequently the need of resources within the cities will increase significantly. This, combined with the 40 % of energy consumption and 36 % of CO2 emissions of the building sector, makes necessary to accelerate the transition towards more sustainable cities. The CITyFiED project contributes to this transition, aiming to develop an innovative and holistic methodological approach for energy-efficient district renovation and deliver three large scale demonstration cases in the cities of Lund (Sweden), Laguna de Duero (Spain) and Soma (Turkey). CITyFiED methodology consists of several phases that ease the decision-making tasks towards the district renovation, considering the energy efficiency as the main pillar and local authorities as clients. For the case of Torrelago district (Spain) the intervention consists of a set of energy conservative measures including the facąde retrofitting of 143.025 m2 of living space in 31 twelve-storey buildings; the renovation of the district heating network with a new biomass thermal plant; the integration of renewable energy sources, including a micro-cogeneration system, and the installation of individual smart meters. After the renovation action, one-year monitoring campaign is ongoing. The CITyFiED monitoring platform will collect information from the energy systems and deliver environmental, technical, economic and social key performance indicators by March 2019. At the end of the project the achievement of the predefined goals will be verified: Up to 36 % of energy saving and 3,429 tons-CO2/yr emissions saving covering the 59,4 % of the energy consumption with renewable sources.The research and results presented in this paper evolve from activities related to the CITyFiED project, which has received funding from the European Commission under the Grant Agreement no. 609129. This article is the result of cooperative research work of many experts from various countries and we would like to gratefully acknowledge the rest of the CITyFiED partners

The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session

Saxagliptin is a potent, selective DPP4 inhibitor. Highlights from abstracts presented at the 2010 meetings of the European Association for the Study of Diabetes and the American Diabetes Association include studies and analyses that shed light on the promising role for saxagliptin within the management of type 2 diabetes mellitus. Data show that saxagliptin combination therapy improves HbA1c levels compared with placebo, particularly in patients with high HbA1c at baseline, long duration of disease, low baseline creatinine clearance, and low homeostasis model assessment 2 β-cell function at baseline. These efficacy benefits are achieved without any increase in hypoglycemia or other adverse events. The study results also show that the saxagliptin plus metformin combination is a good candidate for initial therapy in drug-naïve patients treated for as long as 72 weeks. Survey data presented confirm that hypoglycemia (and fear of hypoglycemia) is a barrier to patients' acceptance of diabetes treatment, limiting its efficacy. Therefore, therapies such as saxagliptin that have a low risk of hypoglycemia may be more acceptable to patients in helping them to achieve glycemic control and to optimize their quality of life. In patients with renal impairment, for whom metformin is contraindicated, saxagliptin monotherapy is a promising option for antidiabetic management as, when given at a reduced dose, it is well-tolerated with a safety profile similar to that of placebo

Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons

We have developed an animal model of degeneration of the nigrostriatal dopaminergic neurons, the neuronal system involved in Parkinson's disease (PD). The implication of neuroinflammation on this disease was originally established in 1988, when the presence of activated microglia in the substantia nigra (SN) of parkinsonians was reported by McGeer et al. Neuroinflammation could be involved in the progression of the disease or even has more direct implications. We injected 2 μg of the potent proinflammatory compound lipopolysaccharide (LPS) in different areas of the CNS, finding that SN displayed the highest inflammatory response and that dopaminergic (body) neurons showed a special and specific sensitivity to this process with the induction of selective dopaminergic degeneration. Neurodegeneration is induced by inflammation since it is prevented by anti-inflammatory compounds. The special sensitivity of dopaminergic neurons seems to be related to the endogenous dopaminergic content, since it is overcome by dopamine depletion. Compounds that activate microglia or induce inflammation have similar effects to LPS. This model suggest that inflammation is an important component of the degeneration of the nigrostriatal dopaminergic system, probably also in PD. Anti-inflammatory treatments could be useful to prevent or slow down the rate of dopaminergic degeneration in this disease

Magnetization of Mn_12 Ac in a slowly varying magnetic field: an ab initio study

Beginning with a Heisenberg spin Hamiltonian for the manganese ions in the Mn_12 Ac molecule, we find a number of low-energy states of the system. We use these states to solve the time-dependent Schrodinger equation and find the magnetization of the molecule in the presence of a slowly varying magnetic field. We study the effects of the field sweep rate, fourth order anisotropic spin interactions and a transverse field on the weights of the different states as well as the magnetization steps which are known to occur in the hysteresis plots in this system. We find that the fourth order term and a slow field sweep rate are crucial for obtaining prominent steps in magnetization in the hysteresis plots.Comment: LaTeX, 11 pages, 12 eps figure

Critical review of technologies for the on-site treatment of hospital wastewater: From conventional to combined advanced processes

In this work, a raw and low cost mineral, ilmenite (FeTiO3), has been tested for the first time as a photocatalyst paired with peroxymonosulfate (HSO5-; PMS) for the inactivation of Enterococcus faecalis as an alternative to conventional treatments to disinfect wastewater for reuse. The influence of some operational parameters such as reagent dosage, catalyst concentration, initial pH, or flow rate was also studied and optimized. After several tests, the scarce pure photoactivity under UV-A was remarked by ilmenite because of its high iron content, which favors photogenerated charge recombination. However, ilmenite activity was highly promoted when combined with low concentrations of PMS and UV-A light, reaching total inactivation of Enterococcus faecalis in 120 min. Quenching tests were performed using methanol, tert-butyl alcohol, furfuryl alcohol, and Cu(II) to assess the main reactive species involved in the disinfection process determining the critical role of both HO·and SO4·- radicals in the process. Finally, the influence of the water matrix was also evaluated by studying the effect of water hardness and the presence of nutrients on the system. Overall, the PMS/Ilmenite/UV-A system yielded promising results with a total removal of Enterococcus faecalis in 120 min. However, it also showed the need for further study and understanding of the disinfection mechanism to achieve the same level of performance in real wastewaterThe "Comunidad de Madrid" supported this research through REMTAVARES S2013/MAE-2716 and S2018/EMT-434

Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study

Introduction: Approximately 100 loci have been definitively associated with rheumatoid arthritis (RA) susceptibility. However, they explain only a fraction of RA heritability. Interactions between polymorphisms could explain part of the remaining heritability. Multiple interactions have been reported, but only the shared epitope (SE) × protein tyrosine phosphatase nonreceptor type 22 (PTPN22) interaction has been replicated convincingly. Two recent studies deserve attention because of their quality, including their replication in a second sample collection. In one of them, researchers identified interactions between PTPN22 and seven single-nucleotide polymorphisms (SNPs). The other showed interactions between the SE and the null genotype of glutathione S-transferase Mu 1 (GSTM1) in the anti-cyclic citrullinated peptide-positive (anti-CCP+) patients. In the present study, we aimed to replicate association with RA susceptibility of interactions described in these two high-quality studies. Methods: A total of 1,744 patients with RA and 1,650 healthy controls of Spanish ancestry were studied. Polymorphisms were genotyped by single-base extension. SE genotypes of 736 patients were available from previous studies. Interaction analysis was done using multiple methods, including those originally reported and the most powerful methods described. Results: Genotypes of one of the SNPs (rs4695888) failed quality control tests. The call rate for the other eight polymorphisms was 99.9%. The frequencies of the polymorphisms were similar in RA patients and controls, except for PTPN22 SNP. None of the interactions between PTPN22 SNPs and the six SNPs that met quality control tests was replicated as a significant interaction term the originally reported finding or with any of the other methods. Nor was the interaction between GSTM1 and the SE replicated as a departure from additivity in anti-CCP+ patients or with any of the other methods. Conclusions: None of the interactions tested were replicated in spite of sufficient power and assessment with different assays. These negative results indicate that whether interactions are significant contributors to RA susceptibility remains unknown and that strict standards need to be applied to claim that an interaction exists